Anavex Life Sciences Strengthens Board of Directors NEW

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
133
Anavex Life Sciences Strengthens Board of Directors

NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL ), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the appointment of Peter Donhauser, D.O. to its Board of Directors.  Dr. Donhauser has more than 20 years of expertise in clinical research followed by practicing osteopathic medicine with an integrated medical approach in private practice since 2000.  He worked at the University Hospital of Munich in the fields of geriatrics and neuromusculoskeletal diseases.  During this time, he was a clinical trial investigator in multiple Phase 3 studies, including studies sponsored by Merck Sharp & Dohme/Merck, Boehringer Mannheim/Roche, Servier and Sanofi.

“I am excited to join the Board of Directors of Anavex Life Sciences at this important juncture,” said Dr. Donhauser.  “Anavex has reported promising 57-week data from its Phase 2a clinical trial in Alzheimer’s patients as well as positive preclinical data across a broad range of CNS diseases. I look forward to working with the team to advance the upcoming clinical programs in Rett syndrome, Parkinson’s and Alzheimer’s disease.”

“We are pleased to welcome Peter Donhauser, D.O. to our Board,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.  “With more than 20 years of experience as a practicing physician and clinical trial investigator in the areas of osteopathic and geriatric medicine, we believe his contributions will be highly valuable as we advance our Alzheimer’s clinical trial program into a larger, placebo-controlled Phase 2/3 study and initiate Phase 2 trials in Rett syndrome and Parkinson’s disease.”

Dr. Donhauser received his human medicine degree at the University of Munich and Doctor of Osteopathic Medicine (D.O.) from the DAAO and EROP at the Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL ) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors and successfully completed Phase 1. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com . You can also connect with the company on Twitter , Facebook and LinkedIn .

To receive ongoing Anavex corporate communications, please click on the following link to join our email alert list: http://www.anavex.com/investors/information-request/ .

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media: Dennis Dobson, Jr. Dobson Media Group 203-258-0159 dennisdobsonjr@dobsonmediagroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 147

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 59

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 114

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 19

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 139

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading

Top 5 Most Recently Viewed Articles

Trinseo Announces New Dividend Amid Strategic Changes Ahead

Updated Category News Views 225

Trinseo Approves Dividend for Shareholders Trinseo (NYSE: TSE), a prominent provider of specialty material solutions, has recently announced a quarterly dividend approved by its Board of Directors. The dividend declared stands at $0.01 per share, set to be distributed on a future date, offering a slight financial incentive for shareholders. To be eligible, shareholders...

Continue Reading
2026 Mighty 25: Celebrating Military Community Leaders

Updated Category News Views 26

A Spotlight on Unsung Heroes Tampa, Florida, just got a little mightier as We Are The Mighty rolls out the red carpet for the 2026 Mighty 25. This annual roll call, backed by CareSource Military & Veterans™, shines a light on veterans, military spouses, creators, entrepreneurs, and change agents defying the status quo. They are redefining impact across the military...

Continue Reading
Rubrik Inc Soars as Earnings Beat Expectations

Updated Category News Views 238

Rubrik Inc's Recent Stock Surge Rubrik, Inc. (NYSE: RBRK) has recently captured the attention of the market as its shares have risen over 20% following an impressive report of fourth-quarter earnings. The company exceeded expectations in both profitability and revenue, which undoubtedly prompted a wave of investor optimism. Financial Performance Highlights For the latest...

Continue Reading
Sanofi’s Amlitelimab Achieves Key Study Goals for Eczema Treatment

Updated Category News Views 284

Sanofi’s Amlitelimab Revolutionizes Atopic Dermatitis Treatment In an exciting development for patients suffering from atopic dermatitis, Sanofi's amlitelimab has met all primary and key secondary endpoints in the pivotal COAST 1 phase 3 study, targeting both adults and adolescents. This innovative medication demonstrated meaningful efficacy in terms of skin clearance...

Continue Reading
Alphamin Resources Corp: Board Changes and Future Outlook

Updated Category News Views 168

Leadership Changes at Alphamin Resources Corp Alphamin Resources Corp., a prominent player in the mining sector, recently shared significant news regarding its board of directors. The company announced the resignation of Mr. Rudolf Pretorius as a director. This change marks a pivotal moment in the company’s leadership structure, as Mr. Pretorius had been with the board...

Continue Reading